

Barbara Stauch Slusher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2305507/publications.pdf>

Version: 2024-02-01

210
papers

12,579
citations

31976

53
h-index

32842

100
g-index

217
all docs

217
docs citations

217
times ranked

14873
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. <i>ELife</i> , 2014, 3, e02523.	6.0	1,296
2	Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells. <i>Cell Metabolism</i> , 2012, 15, 110-121.	16.2	923
3	Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. <i>Science</i> , 2019, 366, 1013-1021.	12.6	643
4	Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1. <i>Cancer Research</i> , 2010, 70, 8981-8987.	0.9	439
5	Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. <i>Journal of Clinical Investigation</i> , 2015, 125, 2293-2306.	8.2	319
6	Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. <i>Nature Medicine</i> , 1999, 5, 1396-1402.	30.7	281
7	Biodistribution, Tumor Detection, and Radiation Dosimetry of ¹⁸ F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1883-1891.	5.0	264
8	Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. <i>EMBO Journal</i> , 2006, 25, 1375-1384.	7.8	241
9	Design, Synthesis, and Biological Activity of a Potent Inhibitor of the Neuropeptidase N-Acetylated Î±-Linked Acidic Dipeptidase. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 619-622.	6.4	230
10	Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. <i>Journal of Clinical Investigation</i> , 2020, 130, 3865-3884.	8.2	230
11	Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E5328-36.	7.1	180
12	Palonosetron triggers 5-HT ₃ receptor internalization and causes prolonged inhibition of receptor function. <i>European Journal of Pharmacology</i> , 2010, 626, 193-199.	3.5	172
13	Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl Sulfide 3 (BPTES) Analogs as Glutaminase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10551-10563.	6.4	163
14	<i>In vitro</i> and <i>In vivo</i> Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016. <i>Clinical Cancer Research</i> , 2009, 15, 607-612.	7.0	156
15	Preventing Allograft Rejection by Targeting Immune Metabolism. <i>Cell Reports</i> , 2015, 13, 760-770.	6.4	156
16	We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1824-1832.	4.1	148
17	The Antiemetic 5-HT ₃ Receptor Antagonist Palonosetron Inhibits Substance P-Mediated Responses <i>In Vitro</i> and <i>In Vivo</i> . <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 362-368.	2.5	123
18	Molecular mechanisms of 5-HT ₃ and NK1 receptor antagonists in prevention of emesis. <i>European Journal of Pharmacology</i> , 2014, 722, 26-37.	3.5	123

#	ARTICLE	IF	CITATIONS
19	Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 9554-9559.	7.1	115
20	Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. <i>Journal of Neurochemistry</i> , 2002, 80, 477-487.	3.9	113
21	Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. <i>Prostate</i> , 2000, 45, 350-354.	2.3	112
22	Pharmacological mechanisms of 5-HT ₃ and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. <i>European Journal of Pharmacology</i> , 2012, 684, 1-7.	3.5	112
23	Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. <i>Drug Discovery Today</i> , 2007, 12, 767-776.	6.4	102
24	Synthesis and Biological Evaluation of Thiol-Based Inhibitors of Glutamate Carboxypeptidase II: Discovery of an Orally Active GCP II Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 1989-1996.	6.4	100
25	Discovery of 6-Diazo-5-oxo-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8621-8633.	6.4	98
26	Characterization of extracellular vesicles and synthetic nanoparticles with four orthogonal single-particle analysis platforms. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12079.	12.2	97
27	Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. <i>Protein Science</i> , 2004, 13, 1627-1635.	7.6	93
28	Incorporation of metabolically stable ketones into a small molecule probe to increase potency and water solubility. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4787-4792.	2.2	93
29	Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (NAAG) hydrolyzing enzyme N-acetylated β -linked acidic dipeptidase (NAALADase). <i>Journal of Comparative Neurology</i> , 1992, 315, 217-229.	1.6	91
30	Design and Pharmacological Activity of Phosphinic Acid Based NAALADase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 4170-4175.	6.4	90
31	Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice. <i>Cancer Research</i> , 2011, 71, 3952-3962.	0.9	85
32	Synthesis and Biological Evaluation of Low Molecular Weight Fluorescent Imaging Agents for the Prostate-Specific Membrane Antigen. <i>Bioconjugate Chemistry</i> , 2012, 23, 2377-2385.	3.6	84
33	Characterization of the enzymatic activity of PSM: Comparison with brain NAALADase. , 1999, 39, 28-35.		82
34	Structural Basis of Interactions between Human Glutamate Carboxypeptidase II and Its Substrate Analogs. <i>Journal of Molecular Biology</i> , 2008, 376, 1438-1450.	4.2	79
35	Mouse brain serine racemase catalyzes specific elimination of L-serine to pyruvate. <i>FEBS Letters</i> , 2003, 535, 44-48.	2.8	78
36	Regional brain distribution of translocator protein using [¹¹ C]DPA-713 PET in individuals infected with HIV. <i>Journal of NeuroVirology</i> , 2014, 20, 219-232.	2.1	78

#	ARTICLE	IF	CITATIONS
37	Cambinol, a Novel Inhibitor of Neutral Sphingomyelinase 2 Shows Neuroprotective Properties. PLoS ONE, 2015, 10, e0124481.	2.5	77
38	Reduced BACE1 Activity Enhances Clearance of Myelin Debris and Regeneration of Axons in the Injured Peripheral Nervous System. Journal of Neuroscience, 2011, 31, 5744-5754.	3.6	76
39	GCP II (NAALADase) Inhibition Suppresses Mossy Fiber-CA3 Synaptic Neurotransmission by a Presynaptic Mechanism. Journal of Neurophysiology, 2004, 91, 182-193.	1.8	75
40	Targeting the Glutamatergic System for the Treatment of HIV-Associated Neurocognitive Disorders. Journal of NeuroImmune Pharmacology, 2013, 8, 594-607.	4.1	75
41	Highly Selective Dopamine D ₃ Receptor (D ₃ R) Antagonists and Partial Agonists Based on Eticlopride and the D ₃ R Crystal Structure: New Leads for Opioid Dependence Treatment. Journal of Medicinal Chemistry, 2016, 59, 7634-7650.	6.4	73
42	Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. European Journal of Pharmacology, 2012, 689, 25-30.	3.5	72
43	Structural Insight into the Pharmacophore Pocket of Human Glutamate Carboxypeptidase II. Journal of Medicinal Chemistry, 2007, 50, 3267-3273.	6.4	71
44	Effect of middle cerebral artery occlusion on mRNA expression for the sodium-coupled vitamin C transporter SVCT2 in rat brain. Journal of Neurochemistry, 2003, 86, 896-906.	3.9	63
45	Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury. Journal of Neurochemistry, 2005, 95, 314-323.	3.9	62
46	Tackling reproducibility in academic preclinical drug discovery. Nature Reviews Drug Discovery, 2015, 14, 733-734.	46.4	62
47	Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects. Neuropsychopharmacology, 2019, 44, 1415-1424.	5.4	61
48	Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay. Analytical Biochemistry, 2002, 310, 50-54.	2.4	60
49	Glutamate Carboxypeptidase Inhibition Reduces the Severity of Chemotherapy-Induced Peripheral Neurotoxicity in Rat. Neurotoxicity Research, 2010, 17, 380-391.	2.7	59
50	Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors. Biochemical and Biophysical Research Communications, 2013, 438, 243-248.	2.1	59
51	Maternal inflammation leads to impaired glutamate homeostasis and up-regulation of glutamate carboxypeptidase II in activated microglia in the fetal/newborn rabbit brain. Neurobiology of Disease, 2016, 94, 116-128.	4.4	59
52	Clinical development of metabolic inhibitors for oncology. Journal of Clinical Investigation, 2022, 132, .	8.2	59
53	Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 10676-10691.	6.4	58
54	Inhibition of Glutamate Carboxypeptidase II (GCP II) activity as a treatment for cognitive impairment in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 20101-20106.	7.1	57

#	ARTICLE	IF	CITATIONS
55	Bringing together the academic drug discovery community. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 811-812.	46.4	56
56	<i>N</i> -(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-L-norleucine (DON) as a Potential Treatment for HIV Associated Neurocognitive Disorders. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7186-7198.	6.4	56
57	Expression and acquisition of the conditioned place preference response to cocaine in rats is blocked by selective inhibitors of the enzyme N-acetylated- γ -linked-acidic dipeptidase (NAALADASE). <i>Synapse</i> , 2001, 41, 22-28.	1.2	55
58	Small molecule glutaminase inhibitors block glutamate release from stimulated microglia. <i>Biochemical and Biophysical Research Communications</i> , 2014, 443, 32-36.	2.1	54
59	Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term Recovery. <i>Cancer Research</i> , 2018, 78, 817-829.	0.9	54
60	Effect of 2-(Phosphono-methyl)-pentanedioic Acid on Allodynia and Afferent Ectopic Discharges in a Rat Model of Neuropathic Pain. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 662-667.	2.5	52
61	Inhibition of NAALADase by 2- <i>MPMPA</i> attenuates cocaine-induced relapse in rats: a NAAG-GluR2/3-mediated mechanism. <i>Journal of Neurochemistry</i> , 2010, 112, 564-576.	3.9	51
62	Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide. <i>Angiogenesis</i> , 2016, 19, 487-500.	7.2	51
63	Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 520-524.	2.8	50
64	Effects of GCP-II inhibition on responses of dorsal horn neurones after inflammation and neuropathy: an electrophysiological study in the rat. <i>Neuropeptides</i> , 2003, 37, 298-306.	2.2	49
65	Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2097-2100.	2.2	46
66	Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma. <i>Translational Oncology</i> , 2019, 12, 1314-1322.	3.7	46
67	High Affinity Dopamine D ₃ Receptor (D ₃ R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D ₃ R Knockout Mice. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6195-6213.	6.4	45
68	Inhibition of Microglia Activation as a Phenotypic Assay in Early Drug Discovery. <i>Journal of Biomolecular Screening</i> , 2014, 19, 17-31.	2.6	43
69	Still NAAG-ing After All These Years. <i>Advances in Pharmacology</i> , 2016, 76, 215-255.	2.0	43
70	Structural Optimization of Thiol-Based Inhibitors of Glutamate Carboxypeptidase II by Modification of the P1 Side Chain. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2876-2885.	6.4	42
71	New Approaches to Chemotherapy-Induced Nausea and Vomiting. <i>Cancer Journal (Sudbury, Mass)</i> , 2006, 12, 341-347.	2.0	42
72	Pharmacokinetics of Oral d-Serine in d-Amino Acid Oxidase Knockout Mice. <i>Drug Metabolism and Disposition</i> , 2012, 40, 2067-2073.	3.3	42

#	ARTICLE	IF	CITATIONS
73	Neuroprotection produced by the NAALADase inhibitor 2-PMPA in rat cerebellar neurons. <i>European Journal of Pharmacology</i> , 2000, 402, 31-37.	3.5	41
74	Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF- β 2. <i>European Journal of Pharmacology</i> , 2001, 430, 33-40.	3.5	41
75	Morphine Tolerance and Reward but not Expression of Morphine Dependence are Inhibited by the Selective Glutamate Carboxypeptidase II (GCP II, NAALADase) Inhibitor, 2-PMPA. <i>Neuropsychopharmacology</i> , 2003, 28, 457-467.	5.4	41
76	DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation. <i>Scientific Reports</i> , 2018, 8, 17715.	3.3	41
77	Neuromuscular NMDA Receptors Modulate Developmental Synapse Elimination. <i>Journal of Neuroscience</i> , 2016, 36, 8783-8789.	3.6	39
78	JHU-083 selectively blocks glutaminase activity in brain CD11b+ cells and prevents depression-associated behaviors induced by chronic social defeat stress. <i>Neuropsychopharmacology</i> , 2019, 44, 683-694.	5.4	38
79	Genetically epilepsy-prone rats have increased brain regional activity of an enzyme which liberates glutamate from N-acetyl-aspartyl-glutamate. <i>Brain Research</i> , 1992, 593, 140-143.	2.2	37
80	Intranasal insulin therapy reverses hippocampal dendritic injury and cognitive impairment in a model of HIV-associated neurocognitive disorders in EcoHIV-infected mice. <i>Aids</i> , 2019, 33, 973-984.	2.2	37
81	Structural Basis for Induction of Peripheral Neuropathy by Microtubule-Targeting Cancer Drugs. <i>Cancer Research</i> , 2016, 76, 5115-5123.	0.9	36
82	Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity. <i>Cancer Research</i> , 2016, 76, 3332-3339.	0.9	36
83	Upregulation of the Glutaminase II Pathway Contributes to Glutamate Production upon Glutaminase 1 Inhibition in Pancreatic Cancer. <i>Proteomics</i> , 2019, 19, e1800451.	2.2	36
84	Tumor-Targeted Delivery of 6-Diazo-5-oxo-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3524-3538.	6.4	36
85	NAALADase (GCP II) inhibition prevents cocaine-kindled seizures. <i>Neuropharmacology</i> , 2002, 43, 348-356.	4.1	35
86	Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. <i>Experimental Brain Research</i> , 2014, 232, 2637-2644.	1.5	35
87	FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities. <i>JCI Insight</i> , 2016, 1, .	5.0	35
88	N-acetylated- β -linked-acidic dipeptidase inhibitor has a neuroprotective effect on mouse retinal ganglion cells after pressure-induced ischemia. <i>Neuroscience Letters</i> , 2000, 292, 134-136.	2.1	34
89	Inhibition of transporter-mediated cystine uptake by sulfasalazine analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6184-6187.	2.2	34
90	The Psychiatric Impact of HIV. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1432-1434.	3.5	34

#	ARTICLE	IF	CITATIONS
91	NaV1.1 inhibition can reduce visceral hypersensitivity. <i>JCI Insight</i> , 2018, 3, .	5.0	34
92	Use of identical assay conditions for cocaine analog binding and dopamine uptake to identify potential cocaine antagonists. <i>Drug and Alcohol Dependence</i> , 1997, 48, 43-50.	3.2	33
93	Modulation of behavioral sensitization to cocaine by NAALADase inhibition. <i>Synapse</i> , 2000, 38, 161-166.	1.2	33
94	Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLC microparticle immunization. <i>Cellular Immunology</i> , 2010, 262, 150-161.	3.0	33
95	Valley of death: A proposal to build a "œtranslational bridge" for the next generation. <i>Neuroscience Research</i> , 2017, 115, 1-4.	1.9	33
96	N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 3918-3929.	6.4	33
97	A novel and potent brain penetrant inhibitor of extracellular vesicle release. <i>British Journal of Pharmacology</i> , 2019, 176, 3857-3870.	5.4	33
98	Immunocytochemical distribution of n-acetylaspartylglutamate in the rat forebrain and glutamatergic pathways. <i>Journal of Chemical Neuroanatomy</i> , 1993, 6, 277-292.	2.1	32
99	Protective Effects of Glutamine Antagonist 6-Diazo-5-Oxo- <sc>l</sc>-Norleucine in Mice with Alphavirus Encephalomyelitis. <i>Journal of Virology</i> , 2016, 90, 9251-9262.	3.4	31
100	Investigation of Novel Primary and Secondary Pharmacophores and 3-Substitution in the Linking Chain of a Series of Highly Selective and Bitopic Dopamine D₃ Receptor Antagonists and Partial Agonists. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9061-9077.	6.4	30
101	Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding. <i>FEBS Journal</i> , 2004, 271, 2782-2790.	0.2	29
102	Using click chemistry toward novel 1,2,3-triazole-linked dopamine D3 receptor ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 4000-4012.	3.0	29
103	6-Hydroxy-1,2,4-triazine-3,5(2<i>H</i>,4<i>H</i>)-dione Derivatives as Novel <sc>d</sc>-Amino Acid Oxidase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7258-7272.	6.4	29
104	Glutamine Antagonist JHU083 Normalizes Aberrant Glutamate Production and Cognitive Deficits in the EcoHIV Murine Model of HIV-Associated Neurocognitive Disorders. <i>Journal of NeuroImmune Pharmacology</i> , 2019, 14, 391-400.	4.1	29
105	Astrocytes deliver CK1 to neurons via extracellular vesicles in response to inflammation promoting the translation and amyloidogenic processing of APP. <i>Journal of Extracellular Vesicles</i> , 2020, 10, e12035.	12.2	29
106	Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. <i>ACS Chemical Neuroscience</i> , 2018, 9, 809-816.	3.5	28
107	High-Throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomain. <i>ACS Chemical Biology</i> , 2022, 17, 17-23.	3.4	28
108	Synthesis and SAR of 1-Hydroxy-1<i>H</i>-benzo[<i>d</i>]imidazol-2(3<i>H</i>)-ones as Inhibitors of <sc>d</sc>-Amino Acid Oxidase. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 839-843.	2.8	27

#	ARTICLE	IF	CITATIONS
109	Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron). <i>Cancer Treatment Reviews</i> , 2015, 41, 904-913.	7.7	27
110	Effects of Paclitaxel and Eribulin in Mouse Sciatic Nerve: A Microtubule-Based Rationale for the Differential Induction of Chemotherapy-Induced Peripheral Neuropathy. <i>Neurotoxicity Research</i> , 2016, 29, 299-313.	2.7	27
111	Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects. <i>Frontiers in Chemistry</i> , 0, 10, .	3.6	27
112	DPP IV inhibitor blocks mescaline-induced scratching and amphetamine-induced hyperactivity in mice. <i>Brain Research</i> , 2005, 1048, 177-184.	2.2	26
113	Design, Synthesis, and Pharmacological Evaluation of Glutamate Carboxypeptidase II (GCP II) Inhibitors Based on Thioalkylbenzoic Acid Scaffolds. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5922-5932.	6.4	26
114	Neuropathy-Inducing Effects of Eribulin Mesylate Versus Paclitaxel in Mice with Preexisting Neuropathy. <i>Neurotoxicity Research</i> , 2013, 24, 338-344.	2.7	26
115	Î-Thiolactones as Prodrugs of Thiol-Based Glutamate Carboxypeptidase II (GCP II) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 243-247.	6.4	26
116	MRI demonstrates glutamine antagonist-mediated reversal of cerebral malaria pathology in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E12024-E12033.	7.1	26
117	The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D ₃ Receptor (D ₃ R) Selective Agonists. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6287-6314.	6.4	26
118	Novel Human Neutral Sphingomyelinase 2 Inhibitors as Potential Therapeutics for Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6028-6056.	6.4	26
119	Small Molecule Inhibitors Targeting Biosynthesis of Ceramide, the Central Hub of the Sphingolipid Network. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 279-297.	6.4	26
120	Enantiospecificity of Glutamate Carboxypeptidase II Inhibition. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 2319-2324.	6.4	25
121	Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration. <i>PLoS ONE</i> , 2015, 10, e0131861.	2.5	25
122	Neurological sequelae induced by alphavirus infection of the CNS are attenuated by treatment with the glutamine antagonist 6-diazo-5-oxo-l-norleucine. <i>Journal of NeuroVirology</i> , 2015, 21, 159-173.	2.1	25
123	Discovery of Orally Available Prodrugs of the Glutamate Carboxypeptidase II (GCP II) Inhibitor 2-Phosphonomethylpentanedioic Acid (2-PMPA). <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2810-2819.	6.4	25
124	Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaine-induced reinstatement of drug-seeking behavior in rats. <i>European Journal of Pharmacology</i> , 2010, 627, 156-161.	3.5	24
125	Phosphonate and phosphinate analogues of N-Acylated Î ³ -glutamylglutamate. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 2189-2192.	2.2	23
126	Orally active glutamate carboxypeptidase II inhibitor 2-MPPA attenuates dizocilpine-induced prepulse inhibition deficits in mice. <i>Brain Research</i> , 2011, 1371, 82-86.	2.2	23

#	ARTICLE	IF	CITATIONS
127	Paclitaxel causes degeneration of both central and peripheral axon branches of dorsal root ganglia in mice. <i>BMC Neuroscience</i> , 2016, 17, 47.	1.9	23
128	Inhibition of neutral sphingomyelinase 2 promotes remyelination. <i>Science Advances</i> , 2020, 6, .	10.3	23
129	Targeting Mitochondria in Tumor-Associated Macrophages using a Dendrimer-Conjugated TSPO Ligand that Stimulates Antitumor Signaling in Glioblastoma. <i>Biomacromolecules</i> , 2020, 21, 3909-3922.	5.4	23
130	Pharmacokinetics and Pharmacodynamics of the Glutamate Carboxypeptidase II Inhibitor 2-MPPA Show Prolonged Alleviation of Neuropathic Pain through an Indirect Mechanism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 406-413.	2.5	22
131	Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine. <i>Clinical Cancer Research</i> , 2019, 25, 5925-5936.	7.0	22
132	Inhibition of glutamate carboxypeptidase II (NAALADase) protects against dynorphin A-induced ischemic spinal cord injury in rats. <i>European Journal of Pharmacology</i> , 2005, 508, 115-122.	3.5	21
133	Discovery of a <i>para</i> -Acetoxy-benzyl Ester Prodrug of a Hydroxamate-Based Glutamate Carboxypeptidase II Inhibitor as Oral Therapy for Neuropathic Pain. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7799-7809.	6.4	21
134	Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1343-1353.	0.7	21
135	Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats. <i>Neuropharmacology</i> , 2018, 131, 96-103.	4.1	21
136	Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin. <i>Neuro-Oncology</i> , 2019, 21, 252-263.	1.2	21
137	Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 255-264.	3.0	21
138	Nipping disease in the bud: nSMase2 inhibitors as therapeutics in extracellular vesicle-mediated diseases. <i>Drug Discovery Today</i> , 2021, 26, 1656-1668.	6.4	21
139	The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa149.	0.7	21
140	Synthesis of kojic acid derivatives as secondary binding site probes of d-amino acid oxidase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3910-3913.	2.2	20
141	Local enema treatment to inhibit FOLH1 /GCP II as a novel therapy for inflammatory bowel disease. <i>Journal of Controlled Release</i> , 2017, 263, 132-138.	9.9	20
142	Microtubule-Targeting Agents Eribulin and Paclitaxel Differentially Affect Neuronal Cell Bodies in Chemotherapy-Induced Peripheral Neuropathy. <i>Neurotoxicity Research</i> , 2017, 32, 151-162.	2.7	20
143	DCC-related developmental effects of abused versus therapeutic-like amphetamine doses in adolescence. <i>Addiction Biology</i> , 2020, 25, e12791.	2.6	20
144	Structure-Activity Relationships for a Series of (Bis(4-fluorophenyl)methyl)sulfinyl Alkyl Alicyclic Amines at the Dopamine Transporter: Functionalizing the Terminal Nitrogen Affects Affinity, Selectivity, and Metabolic Stability. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 2343-2357.	6.4	20

#	ARTICLE	IF	CITATIONS
145	Dose-dependent inhibition of GCP II to prevent and treat cognitive impairment in the EAE model of multiple sclerosis. <i>Brain Research</i> , 2016, 1635, 105-112.	2.2	19
146	D-Amino-Acid Oxidase Inhibition Increases D-Serine Plasma Levels in Mouse But not in Monkey or Dog. <i>Neuropsychopharmacology</i> , 2016, 41, 1610-1619.	5.4	19
147	Role of Academic Drug Discovery in the Quest for New CNS Therapeutics. <i>ACS Chemical Neuroscience</i> , 2017, 8, 429-431.	3.5	19
148	Discovery of Benzamidine- and 1-Aminoisoquinoline-Based Human MAS-Related G-Protein-Coupled Receptor X1 (MRGPRX1) Agonists. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8631-8641.	6.4	19
149	Unprecedented Binding Mode of Hydroxamate-Based Inhibitors of Glutamate Carboxypeptidase II: Structural Characterization and Biological Activity. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4539-4550.	6.4	18
150	Glutamine antagonist-mediated immune suppression decreases pathology but delays virus clearance in mice during nonfatal alphavirus encephalomyelitis. <i>Virology</i> , 2017, 508, 134-149.	2.4	18
151	The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 397-408.	4.1	18
152	Dendrimer-2PMPA selectively blocks upregulated microglial GCP II activity and improves cognition in a mouse model of multiple sclerosis. <i>Nanotheranostics</i> , 2022, 6, 126-142.	5.2	18
153	The Orally Active Glutamate Carboxypeptidase II Inhibitor E2072 Exhibits Sustained Nerve Exposure and Attenuates Peripheral Neuropathy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 343, 746-754.	2.5	17
154	Property-Guided Synthesis of Aza-Tricyclic Indolines: Development of Gold Catalysis En Route. <i>Advanced Synthesis and Catalysis</i> , 2016, 358, 1482-1490.	4.3	17
155	Inhibition of neutral sphingomyelinase 2 reduces extracellular vesicle release from neurons, oligodendrocytes, and activated microglial cells following acute brain injury. <i>Biochemical Pharmacology</i> , 2021, 194, 114796.	4.4	17
156	Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces Apoptosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 336-344.	1.7	16
157	GCP II inhibition rescues neurons from gp120III β -induced neurotoxicity. <i>Journal of NeuroVirology</i> , 2009, 15, 449-457.	2.1	15
158	Structure-Activity Relationship Studies on a Series of 3 \pm -[Bis(4-fluorophenyl)methoxy]tropanes and 3 \pm -[Bis(4-fluorophenyl)methylamino]tropanes As Novel Atypical Dopamine Transporter (DAT) Inhibitors for the Treatment of Cocaine Use Disorders. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 10172-10187.	6.4	15
159	Chrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models. <i>European Journal of Pharmacology</i> , 2018, 840, 89-103.	3.5	15
160	Looking for Drugs in All the Wrong Places: Use of GCP II Inhibitors Outside the Brain. <i>Neurochemical Research</i> , 2020, 45, 1256-1267.	3.3	15
161	Glutamine Antagonist JHU-083 Normalizes Aberrant Hippocampal Glutaminase Activity and Improves Cognition in APOE4 Mice. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 437-447.	2.6	15
162	Abnormal acidic amino acids and N-acetylaspartylglutamate in hereditary canine motoneuron disease. <i>Brain Research</i> , 1993, 629, 305-309.	2.2	14

#	ARTICLE	IF	CITATIONS
163	2-MPPA, a selective glutamate carboxypeptidase II inhibitor, attenuates morphine tolerance but not dependence in C57/Bl mice. <i>Psychopharmacology</i> , 2005, 183, 275-284.	3.1	14
164	Bioanalytical method for evaluating the pharmacokinetics of the GCP-II inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA). <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 88, 162-169.	2.8	14
165	High-Throughput Assay Development for Cystine-Glutamate Antiporter (xc-) Highlights Faster Cystine Uptake than Glutamate Release in Glioma Cells. <i>PLoS ONE</i> , 2015, 10, e0127785.	2.5	14
166	Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry. <i>Analytical Biochemistry</i> , 2015, 474, 28-34.	2.4	14
167	The Low-Affinity Binding of Second Generation Radiotracers Targeting TSPO is Associated with a Unique Allosteric Binding Site. <i>Journal of NeuroImmune Pharmacology</i> , 2018, 13, 1-5.	4.1	14
168	The discovery and structure-activity relationships of indole-based inhibitors of glutamate carboxypeptidase II. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 7222-7225.	2.2	13
169	Glutamate Carboxypeptidase II Inhibition Behaviorally and Physiologically Improves Pyridoxine-Induced Neuropathy in Rats. <i>PLoS ONE</i> , 2014, 9, e102936.	2.5	13
170	Enhanced Oral Bioavailability of 2-(Phosphonomethyl)-pentanedioic Acid (2-PMPA) from its (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL)-Based Prodrugs. <i>Molecular Pharmaceutics</i> , 2019, 16, 4292-4301.	4.6	13
171	Inhibition of glutamate-carboxypeptidase-II in dorsolateral prefrontal cortex: potential therapeutic target for neuroinflammatory cognitive disorders. <i>Molecular Psychiatry</i> , 2022, 27, 4252-4263.	7.9	13
172	d-Amino acid oxidase inhibitors based on the 5-hydroxy-1,2,4-triazin-6(1H)-one scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2088-2091.	2.2	12
173	Glutamine antagonism attenuates physical and cognitive deficits in a model of MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	6.0	12
174	Glutamate Carboxypeptidase II in Aging Rat Prefrontal Cortex Impairs Working Memory Performance. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 760270.	3.4	12
175	Gastrointestinal delivery of propofol from fospropofol: its bioavailability and activity in rodents and human volunteers. <i>Journal of Translational Medicine</i> , 2015, 13, 170.	4.4	11
176	Development of a primary microglia screening assay and its use to characterize inhibition of system xc- by erastin and its analogs. <i>Biochemistry and Biophysics Reports</i> , 2017, 9, 266-272.	1.3	11
177	Neutral sphingomyelinase 2 inhibitors based on the 4-(1H-imidazol-2-yl)-2,6-dialkoxyphenol scaffold. <i>European Journal of Medicinal Chemistry</i> , 2019, 170, 276-289.	5.5	11
178	Neutral sphingomyelinase 2 inhibition attenuates extracellular vesicle release and improves neurobehavioral deficits in murine HIV. <i>Neurobiology of Disease</i> , 2022, 169, 105734.	4.4	11
179	Comprehensive Metabolic Profiling of MYC-Amplified Medulloblastoma Tumors Reveals Key Dependencies on Amino Acid, Tricarboxylic Acid and Hexosamine Pathways. <i>Cancers</i> , 2022, 14, 1311.	3.7	10
180	The pathogenesis of, and pharmacological treatment for, Canavan disease. <i>Drug Discovery Today</i> , 2022, 27, 2467-2483.	6.4	10

#	ARTICLE	IF	CITATIONS
181	Dendrimer-2PMPA Delays Muscle Function Loss and Denervation in a Murine Model of Amyotrophic Lateral Sclerosis. <i>Neurotherapeutics</i> , 2022, 19, 274-288.	4.4	9
182	Enhanced Brain Delivery of 2-(Phosphonomethyl)pentanedioic Acid Following Intranasal Administration of Its β -Substituted Ester Prodrugs. <i>Molecular Pharmaceutics</i> , 2017, 14, 3248-3257.	4.6	8
183	Thieno[2,3- <i>d</i>]pyrimidine-Based Positive Allosteric Modulators of Human Mas-Related G Protein-Coupled Receptor X1 (MRGPRX1). <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3218-3228.	6.4	8
184	Reversible Disulfide Formation of the Glutamate Carboxypeptidase II Inhibitor E2072 Results in Prolonged Systemic Exposures In Vivo. <i>Drug Metabolism and Disposition</i> , 2012, 40, 2315-2323.	3.3	7
185	Sowing the Seeds of Discovery: Tau-Propagation Models of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3499-3509.	3.5	7
186	Toxicity induced by a polyglutamated folate analog is attenuated by NAALADase inhibition. <i>Brain Research</i> , 1999, 843, 48-52.	2.2	6
187	Bioanalysis of N-acetyl-aspartyl-glutamate as a marker of glutamate carboxypeptidase II inhibition. <i>Analytical Biochemistry</i> , 2010, 404, 94-96.	2.4	6
188	Glutamate Carboxypeptidase II. , 2013, , 1620-1627.		6
189	Structural basis for potent inhibition of d-amino acid oxidase by thiophene carboxylic acids. <i>European Journal of Medicinal Chemistry</i> , 2018, 159, 23-34.	5.5	6
190	Allosteric kidney-type glutaminase (GLS) inhibitors with a mercaptoethyl linker. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115698.	3.0	6
191	Bioenergetic adaptations to HIV infection. Could modulation of energy substrate utilization improve brain health in people living with HIV-1?. <i>Experimental Neurology</i> , 2020, 327, 113181.	4.1	6
192	Structure-Metabolism Relationships in the Glucuronidation of α -Amino Acid Oxidase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 1251-1253.	2.8	5
193	Peptidomimetics of Arg-Phe-NH ₂ as small molecule agonists of Mas-related gene C (MrgC) receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 5831-5837.	3.0	5
194	Oral administration of D-alanine in monkeys robustly increases plasma and cerebrospinal fluid levels but experimental D-amino acid oxidase inhibitors had minimal effect. <i>Journal of Psychopharmacology</i> , 2016, 30, 887-895.	4.0	5
195	The NAAG-Ming Concerns of Modeling Human Alzheimer's Disease in Mice. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 939-945.	2.6	5
196	TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma. <i>Cancer Letters</i> , 2021, 504, 137-145.	7.2	5
197	High Throughput Screening Cascade To Identify Human Aspartate N-Acetyltransferase (ANAT) Inhibitors for Canavan Disease. <i>ACS Chemical Neuroscience</i> , 2021, 12, 3445-3455.	3.5	5
198	Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme. <i>FASEB Journal</i> , 2013, 27, 2620-2625.	0.5	4

#	ARTICLE	IF	CITATIONS
199	Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement. <i>Current Drug Metabolism</i> , 2021, 22, 735-745.	1.2	4
200	Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclox-induced cytotoxicity in atypical teratoid/rhabdoid tumors. <i>Cell Death and Disease</i> , 2022, 13, 410.	6.3	4
201	Regulatory T cells reduce endothelial neutral sphingomyelinase 2 to prevent T cell migration into tumors. <i>European Journal of Immunology</i> , 2021, 51, 2317-2329.	2.9	3
202	A shot in the arm for cocaine addiction. <i>Nature Medicine</i> , 1996, 2, 26-27.	30.7	2
203	Spontaneous Loss-of-Function Dock2 Mutation Alters Murine Colitis Sensitivity and Is a Confounding Variable in Inflammatory Bowel Disease Research. <i>Crohn's & Colitis</i> 360, 2019, 1, .	1.1	2
204	Model studies towards prodrugs of the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) containing a diazo precursor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 50, 128321.	2.2	2
205	An efficient synthetic route to l- ¹³ C-methyleneglutamine and its amide derivatives, and their selective anticancer activity. <i>RSC Advances</i> , 2021, 11, 7115-7128.	3.6	1
206	OTME-9. Comprehensive Metabolic Profiling Of high MYC Medulloblastoma Reveals Key Differences Between In Vitro And In Vivo Glucose And Glutamine Usage. <i>Neuro-Oncology Advances</i> , 2021, 3, ii15-ii15.	0.7	1
207	Glutamine antagonist JHU083 improves psychosocial behavior and sleep deficits in EcoHIV-infected mice. <i>Brain, Behavior, & Immunity - Health</i> , 2022, 23, 100478.	2.5	1
208	FSMP-18. COMPREHENSIVE METABOLIC PROFILING OF HIGH MYC MEDULLOBLASTOMA REVEALS KEY DIFFERENCES BETWEEN IN VITRO AND IN VIVO GLUCOSE AND GLUTAMINE USAGE. <i>Neuro-Oncology Advances</i> , 2021, 3, i19-i19.	0.7	0
209	Abstract 2321: Comprehensive metabolic profiling of high MYC medulloblastoma revealed key differences between in vitro and in vivo in glucose and glutamine usage. , 2021, , .		0
210	A Novel Oral Glutamate Carboxypeptidase II Inhibitor for the Treatment of Inflammatory Bowel Disease. <i>FASEB Journal</i> , 2022, 36, .	0.5	0